HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cho, S. Y. Articles by Wahl, R. L. Search for Related Content PubMed PubMed Citation Articles by Cho, S. Y. Articles by Wahl, R. L.

In Vitro Evaluation of Adenosine 5'-Monophosphate as an Imaging Agent of Tumor Metabolism

¹ Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland; and ² Department of Radiation Oncology, Tufts-New England Medical Center, Boston, Massachusetts

Correspondence: For correspondence or reprints contact: Richard L. Wahl, Division of Nuclear Medicine, Department of Radiology, JHOC 3223A, 601 N. Caroline St., Baltimore, MD 21287. E-mail: rwahl{at}jhmi.edu

Adenosine appears to play an important role in tumor growth and metastasis. Synthesized ¹¹C-adenosine 5'-monophosphate (AMP) has recently been reported as a potential tumor-imaging radiotracer. Methods: A variety of human tumor cell lines (SKOV-3, SCC-15, U251, U87, Raji, and Daudi) were incubated with 3.7 kBq (0.1 µCi) of [2-³H]AMP (³H-AMP), [5,6-³H]FDG (³H-FDG), or [2-³H]adenosine (³H-adenosine) in low-physiologic-glucose serum-free medium. Selected cells were exposed to caffeine, dipyridamole, adenosine 5'-(,ß-methylene)diphosphate (APCP), or unlabeled adenosine before exposure to the radiotracer. R-phycoerythrin–conjugated mouse antihuman monoclonal antibody to human CD73 was used for immunophenotyping. High-performance liquid chromatography was used to characterize the intracellular metabolites of ³H-AMP after intracellular uptake. Results: Intracellular uptake of ³H-AMP was significant—10 to 100 times the uptake of ³H-FDG, depending on the particular tumor cell line. Preexposure of SKOV-3 cells to caffeine, a competitive inhibitor of adenosine receptors, did not affect cellular uptake of ³H-AMP. However, preexposure of SKOV-3 cells to dipyridamole, an equilibrative nucleoside transporter inhibitor; APCP, a CD73 (ecto-5'-nucleotidase) inhibitor; or cold adenosine significantly inhibited cellular uptake of ³H-AMP. SKOV-3 uptake of ³H-adenosine was inhibited by dipyridamole but not APCP. U251 uptake of ³H-AMP was significantly inhibited by dipyridamole and APCP. U87 uptake of ³H-AMP was only partially inhibited by dipyridamole and APCP. However, Raji and Daudi cells had significantly lower uptake of ³H-AMP than of ³H-FDG but had significantly increased uptake of ³H-adenosine, which was inhibited by dipyridamole. Raji and Daudi cells were negative, but the SKOV-3 cells positive, for CD73 cell-surface expression. ³H-Adenosine metabolites were persistently retained after influx into the cell, predominantly as ³H-adenosine triphosphate and ³H-adenosine diphosphate. Conclusion: Cancer cell lines evaluated in vitro had significantly elevated uptake of radiolabeled AMP, on the order of 10- to100-fold, in comparison to radiolabeled FDG. The mechanism of intracellular uptake depends predominantly on equilibrative nucleoside transporters after conversion of AMP to adenosine by CD73 in SKOV-3, SCC-15, and U251 cells. Intracellular retention is due to phosphorylation to adenosine triphosphate and adenosine diphosphate. Raji and Daudi cells have low uptake of radiolabeled AMP because of a lack of CD73 expression. This in vitro evaluation using ³H-AMP with tumor cell lines supports the potential of ¹¹C-AMP for use in targeting the nucleoside transport pathway in PET imaging of tumors.

Key Words: oncology • PET • [2-³H]adenosine 5'-monophosphate • in vitro • cancer cells • nucleoside transporter

This article has been cited by other articles:

				J. Stagg, U. Divisekera, N. McLaughlin, J. Sharkey, S. Pommey, D. Denoyer, K. M. Dwyer, and M. J. Smyth Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis PNAS, January 26, 2010; 107(4): 1547 - 1552. [Abstract] [Full Text] [PDF]